OX40:OX40L axis: Emerging targets for immunotherapy of human disease

Current Immunology Reviews

Volumn 2, Issue 1, 2006, Pages 37-53

  Salek Ardakani, Shahram ^a   Song, Aihua ^a   Humphreys, Ian R ^a   Croft, Michael ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Allergy; Autoimmunity; Cancer; Immunotherapy; OX40; OX40L; T cells; Transplantation; Viruses

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIVIRUS AGENT; B7 ANTIGEN; BETA INTERFERON; BINDING PROTEIN; CD134 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; ETANERCEPT; GLATIRAMER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; OX40 LIGAND MONOCLONAL ANTIBODY; OX40 MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN OX40L; RECOMBINANT HUMAN INSULIN; RETINOID DERIVATIVE; RITUXIMAB; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC ASTHMA; AUTOIMMUNITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON CANCER; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DIABETOGENESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENTERITIS; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; HISTOCOMPATIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MONITORING; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOMA; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PATHOPHYSIOLOGY; POXVIRUS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; VIRUS RECOMBINANT;

EID: 33745888070     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339506775471884     Document Type: Review

References (202)

1. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immu,nol 2003; 3: 609-20.
2. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling Nat Rev Immunol 2003; 3: 939-51.
3. Paterson DJ, Jefferies WA, Green JR, et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987; 24: 1281-90.
4. Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. EMBO J 1990; 9: 1063-8.
5. Calderhead DM, Buhlmann JE, van den Eertwegh AJ, et al. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 1993; 151: 5261-71.
6. Baum PR, Gayle RB, Ramsdell F, et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J 1994; 13: 3 992-4001.
7. al-Shamkhani A, Birkeland ML, Puklavec M, et al. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand Ent J Immunol 1996; 26: 1695-9.
8. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. Costimulation of CD8 T cell responses by OX40. J Immunol 2004; 172: 4821-5.
9. Kotani A, Ishikawa T, Matsumura Y, et al. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3162-4.
10. Birkeland ML, Copeland NG, Gilbert DJ, Jenkins NA, Barclay AN. Gene structure and chromosomal localization of the mouse homologue of rat OX40 protein. Eur J Immunol 1995; 25: 926-30.
11. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161: 6510-7.
12. Salek-Ardakani S, Song J, Halteman BS, et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 2003; 198: 315-24.
13. Miura S, Ohtani K, Numata N, et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol 1991; 11: 1313-25.
14. Baum PR, Gayle RB, Ramsdell F, et al. Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor. Circ Shock 1994; 44: 30-4.
15. Takasawa N, Ishii N, Higashimura N, et al. Expression of gp34 (OX40 ligand) and OX40 on human T cell clones. Jpn J Cancer Res 2001; 92: 377-82.
16. Wang HC, Klein JR. Multiple levels of activation of murine CD8(+) intraepithelial lymphocytes defined by OX40 (CD134) expression: effects on cell-mediated cytotoxicity, IFN-gamma, and IL-10 regulation. J Immunol 2001; 167: 6717-23.
17. Stuber E, Neurath M, Calderhead D, Fell HP, Strober W. Crosslinking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995; 2: 507-21.
18. Murata K, Ishii N, Takano H, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 2000; 191: 365-74.
19. Ohshima Y, Tanaka Y, Tozawa H, et al. Expression and function of OX40 ligand on human dendritic cells J Immunol 1997; 159: 3838-48.
20. Tanaka H, Demeure CE, Rubio M, Delespesse G, Sarfati M. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Thl/Th2 effectors. Role of stimulator/ responder ratio. J Exp Med 2000; 192: 405-12.
21. Kim MY, Gaspal FM, Wiggett HE, et al. CD4(+)CD3(-) accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells. Immunity 2003; 18: 643-54.
22. Ito T, Amakawa R, Inaba M, et al. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol 2004; 172: 4253-9.
23. Zingoni A, Sornasse T, Cocks BG, et al. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Iummunol 2004; 173: 3716-24.
24. Kashiwakura J, Yokoi H, Saito H, Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 2004; 173: 5247-57.
25. Burgess JK, Carlin S, Pack RA, et al. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J Allergy Clin Iummunol 2004; 113: 683-9.
26. Burgess JK, Blake AE, Boustany S, et al. CD40 and OX40 ligand are increased on stimulated asthmatic airway smooth muscle. J Allergy Clin Immunol 2005; 115: 302-8.
27. Imura A, Hori T, Imada K, et al. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration Blood 1997; 89: 2951-8.
28. Kunitomi A, Hori T, Imura A, Uchiyama T. Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system. J Leukoc Biol 2000; 68: 111-8.
29. Kotani A, Hori T, Matsumura Y, Uchiyama T. Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5. Immunol Lett 2002; 84:1-7.
30. Akiba H, Oshima H, Takeda K, et al. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J Immunol 1999; 162: 7058-66.
31. Sato T, Ishii N, Murata K, et al. Consequences of OX40-OX40 ligand interactions in langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice. Eur J Immunol 2002; 32: 3326-35.
32. Wang Q, Chen Y, Ge Y, et al. Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCs. Tissue Antigens 2004; 64: 566-74.
33. Gramaglia I, Jember A, Pippig SD, et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000; 165: 3043-50.
34. Maxwell JR, Weinberg A, Prell RA, Vella AT. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000; 164: 107-12.
35. Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immnol 2001; 167:6804-11.
36. Chen AI, McAdam AJ, Buhlmann JE, et al. Ox4O-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999; 11: 689-98.
37. Kopf M, Ruedl C, Schmitz N, et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 1999; 11: 699-708.
38. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001, 15: 445-55.
39. Song J, Salek-Ardakani S, Rogers PR, et al. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol 2004; 5: 150-8.
40. Flugel A, Berkowicz T, Ritter T, et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001; 14: 547-60.
41. Weinberg AD, Wallin JJ, Jones RE, et al. Target organ-specific upregulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J Immunol 1994; 152: 4712-21.
42. Boot EP, Koning GA, Storm G, et al. CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. Arthritis Res Ther 2005; 7: R604-15.
43. Brugnoni D, Bettinardi A, Malacarne F, Airo P, Cattaneo R. CD134/OX40 expression by synovial fluid CD4+ T lymphocytes in chronic synovitis. Br J Rheumatol 1998; 37: 584-5.
44. Yoshioka T, Nakajima A, Akiba H, et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000; 30: 2815-23.
45. Giacomelli R, Passacantando A, Perricone R, et al. T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. Clin Exp Rheumatol 2001; 19: 317-20.
46. Pakala SV, Bansal-Pakala P, Halteman BS, Croft M. Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions. Eur J Immunol 2004; 34: 3039-46.
47. Kotani A, Takahashi A, Koga H, et al. Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells. Eur J Haematol 2002; 69: 318-20.
48. Stuber E, Buschenfeld A, Luttges J, et al. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur J Clin Invest 2000; 30: 594-9.
49. Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdC-AM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999; 45: 856-63.
50. Sanchez J, Casano J, Alvarez MA, et al. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2004; 126: 697-703.
51. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2: 762-4.
52. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
53. Buenafe AC, Tsu RC, Bebo B, Jr., et al. A TCR V alpha CDR3-specific motif associated with Lewis rat autoimmune encephalomyelitis and basic protein-specific T cell clones. J Immunol 1997; 158: 5472-83.
54. Nohara C, Akiba H, Nakajima A, et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol 2001; 166: 2108-15.
55. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999; 162: 1818-26.
56. Carboni S, Aboul-Enein F, Waltzinger C, et al. CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol 2003; 145: 1-11.
57. Weinberg AD, Bourdette DN, Sullivan TJ, et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996; 2: 183-9.
58. Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J Immunol 2001; 167: 2991-9.
59. Chitnis T, Najafian N, Abdallah KA, et al. CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001; 107: 575-83.
60. Kaleeba JA, Offner H, Vandenbark AA, Lublinski A, Weinberg AD. The OX40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells. Int Immunol-1998; 10: 453-61.
61. Bach JF, Chatenoud L, Herbelin A, Gombert JM, Carnaud C. Autoimmune diabetes: how many steps for one disease? Res Immunol 1997; 148: 332-8.
62. Casares S, Brumeanu TD. Insights into the pathogenesis of type 1 diabetes: a hint for novel immunospecific therapies. Curr Mol Med 2001; 1: 357-78.
63. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85: 291-7.
64. Trucco M, Giannoukakis N. Type 1 diabetes: MHC tailored for diabetes cell therapy. Gene Ther 2005; 12: 553-4.
65. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710-9.
66. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145-55.
67. Balasa B, Krahl T, Patstone G, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159: 4620-7.
68. Martin-Orozco N, Chen Z, Poirot L, et al. Paradoxical dampening of anti-islet self-reactivity but promotion of diabetes by OX40 ligand. J Immunol 2003; 171: 6954-60.
69. Panayi GS, Corrigall VM, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001; 27: 317-34.
70. Feldmann M. What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis? Int Arch Allergy Immunol 1996; 111: 362-5.
71. Goldblatt F, Isenberg DA. New therapies for rheumatoid arthritis. Clin Exp Immunol 2005; 140: 195-204.
72. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001; 19: 163-96.
73. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Semin Arthritis Rheum 2005; 34: 819-36.
74. Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells, J Immunol 2001; 167: 90-7.
75. Horai R, Nakajima A, Habiro K, et al. TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest 2004; 114: 1603-11.
76. Rachmilewitz D, Stamler JS, Bachwich D, et al. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 1995; 36: 718-23.
77. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
78. Gordon JN, Sabatino AD, Macdonald TT. The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr Opin Gastroenterol 2005; 21: 431-7.
79. Guarner F. The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr Opin Gastroenterol 2005; 21: 414-8.
80. Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 1993; 178: 237-44.
81. Leach MW, Bean AG, Mauze S, Coffman RL, Powrie F. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol 1996; 148: 1503-15.
82. Powrie F, Mauze S, Coffman RL. CD4+ T-cells in the regulation of inflammatory responses in the intestine. Res Immunol 1997; 148: 576-81.
83. Malmstrom V, Shipton D, Singh B, et al. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol 2001; 166: 6972-81.
84. Totsuka T, Kanai T, Uraushihara K, et al. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2003; 284: G595-603.
85. Higgins LM, McDonald SA, Whittle N, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 1999; 162: 486-93.
86. Obermier F, Schwarz H, Dunger N, et al. OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in mice. Eur J Immunol 2003; 33: 3265-74.
87. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-74.
88. Klingebiel T, Schlegel PG. GVHD: overview on pathophysiology, incidence, clinical and biological features. Bone Marrow Transplant 1998; 21 Suppl 2: S45-9.
89. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-8.
90. Theobald M. Allorecognition and graft-versus-host disease. Bone Marrow Transplant 1995; 15: 489-98.
91. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood 1997; 89: 4652-8.
92. Lamb LS, Jr., Gee AP, Parrish RS, et al. Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor: clinical and immunologic characteristics. Bone Marrow Transplant 1996; 17: 1021-7.
93. Gadisseur AP, Gratama JW, Lamers C, et al. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation. Bone Marrow Transplant 1999; 23: 1013-7.
94. Stuber E, Von Freier A, Marinescu D, Folsch UR. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology 1998; 115: 1205-15.
95. Tsukada N, Akiba H, Kobata T, et al. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 2000; 95: 2434-9.
96. Blazar BR, Sharpe AH, Chen AI, et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 2003; 101: 3741-8.
97. Curry AJ, Chikwe J, Smith XG, et al. OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival. Transplantation 2004; 78: 807-14.
98. Tian L, Guo W, Yuan Z, et al. Association of the CD134/CD134L costimulatory pathway with acute rejection of small bowel allograft. Transplantation 2002; 74: 133-8.
99. Li XC, Li Y, Dodge I, et al. Induction of allograft tolerance in the absence of Fas-mediated apoptosis. J Immunol 1999; 163: 2500-7.
100. Xu H, Elster EA, Blair PJ, et al. Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation. Am J Transplant 2003; 3: 1350-4.
101. Vu MD, Amanullah F, Li Y, et al. Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection. J Immunol 2004; 173: 214-21.
102. Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004; 172: 1691-8.
103. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999; 17: 255-81.
104. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Asthma:: an epidemic of dysregulated immunity. Nat Immunol 2002; 3: 715-20.
105. Krinzman SJ, De Sanctis GT, Cernadas M, et al. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J Clin Invest 1996; 98: 2693-9.
106. Keane-Myers A, Gause WC, Linsley PS, Chen SJ, Wills-Karp M. B7-CD28/ CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens. J Immunol 1997; 158: 2042-9.
107. Deurloo DT, van Berkel MA, van Esch BC, et al. CD28/CTLA4 double deficient mice demonstrate crucial role for B7 co-stimulation in the induction of allergic lower airways disease. Clin Exp Allergy 2003; 33: 1297-304.
108. Coyle AJ, Gutierrez-Ramos JC. The role of ICOS and other costimulatory molecules in allergy and asthma. Springer Semin Immunopathol 2004; 25: 349-59.
109. Gonzalo JA, Tian J, Delaney T, et al. ICOS is critical for T helper cell-mediated lung mucosal. inflammatory responses. Nat Immunol 2001; 2: 597-604.
110. Kimzey SL, Liu P, Green JM. Requirement for CD28 in the effector phase of allergic airway inflammation. J Immunol 2004; 173: 632-40.
111. Akiba H, Miyahira Y, Atsuta M, et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 2000; 191: 375-80.
112. Ohshima Y, Yang LP, Uchiyama T, et al. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors, Blood 1998; 92: 3338-45.
113. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998; 188: 297-304.
114. Delespesse G, Ohshima Y, Yang LP, Demeure C, Sarfati M. OX40-Mediated cosignal enhances the maturation of naive human CD4+ T cells into high IL-4-producing effectors. Int Arch Allergy Immunol 1999; 118: 384-6.
115. Linton PJ, Bautista B, Biederman E, et al. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med 2003; 197: 875-83.
116. Ishii N, Ndhlovu LC, Murata K, et al. OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses. Eur J Immunol 2003; 33: 2372-81.
117. Ekkens MJ, Liu Z, Liu Q, et al. The role of OX40 ligand interactions in the development of the Th2 response to the gastrointestinal nematode parasite Heliginosomoides polygyrus. J Immunol 2003; 170: 384-93.
118. Jember AG, Zuberi R, Liu FT, Croft M. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J Exp Med 2001; 193: 387-92.
119. Arestides RS, He H, Westlake RM, et al. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur J Immunol 2002; 32: 2874-80.
120. Pippig SD, Pena-Rossi C, Long J, et al. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J Immunol 1999; 163: 6520-9.
121. Humphreys IR, Walzl G, Edwards L, et al. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J Exp Med 2003; 198: 1237-42.
122. Humphreys IR, Edwards L, Walzl G, et al. OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J Immunol 2003; 170: 6125-32.
123. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004; 4: 420-31.
124. Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 2004; 112: 559-66.
125. Grosenbach DW, Schlom J, Gritz L, Gomez Yafal A, Hodge JW. A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production. Cell Immunol 2003; 222: 45-57.
126. Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 2001; 31: 2566-73.
127. Xu L, Yoon H, Zhao MQ, et al. Cutting edge: pulmonary immunopathology mediated by antigen-specific expression of TNF-alpha by antiviral CD8+ T cells. J Immunol 2004; 173: 721-5.
128. Enelow RI, Mohammed AZ, Stoler MH, et al. Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease. J Clin Invest 1998; 102: 1653-61.
129. Lumsden JM, Roberts JM, Harris NL, Peach RJ, Ronchese F. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection. J Immunol 2000; 164: 79-85.
130. Shimojima M, Miyazawa T, Ikeda Y, et al. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 2004; 303: 1192-5.
131. de Parseval A, Chatterji U, Sun P, Elder JH. Feline immunodeficiency virus targets activated CD4+ T cells by using CD 134 as a binding receptor. Proc Natl Acad Sci USA 2004; 101: 13044-9.
132. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
133. Pankow R, Durkop H, Latza U, et al. The HTLV-I tax protein transcriptionally modulates OX40 antigen expression. J Immunol 2000; 165: 263-70.
134. Benedict CA, Banks TA, Ware CF. Death and survival: viral regulation of TNF signaling pathways. Curr Opin Immunol 2003; 15: 59-65.
135. Kunitomi A, Hori T, Maeda M, Uchiyama T. OX40 signaling renders adult T-cell leukemia cells resistant to Fas-induced apoptosis. Int J Hematol 2002; 76: 260-6.
136. Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J 1989; 8: 4251-8.
137. Yurochko AD, Kowalik TF, Huong SM, Huang ES. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/ p50 and p65 promoters. J Virol 1995; 69: 5391-400.
138. DeLuca C, Kwon H, Lin R, Wainberg M, Hiscott J. NF-kappaΒ activation and HIV-1 induced apoptosis. Cytokine Growth Factor Rev 1999; 10: 235-53.
139. Benedict CA, Angulo A, Patterson G, et al. Neutrality of the canonical NF-kappaB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro. J Virol 2004; 78: 741-50.
140. Takahashi Y, Tanaka Y, Yamashita A, et al. OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. J Virol 2001; 75: 6748-57.
141. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995; 7: 682-6.
142. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000; 12: 589-96.
143. Zitvogel L, Robbins PD, Storkus WJ, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996; 26: 1335-41.
144. Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer 1998; 77: 107-13.
145. Sumimoto H, Tani K, Nakazaki Y, et al. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice Int J Cancer 1997; 73: 556-61.
146. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999; 11: 203-10.
147. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173: 7125-30.
148. Shrikant P, Mescher MF. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol 1999; 162: 2858-66.
149. Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 2005; 28: 53-62.
150. Vetto JT, Lum S, Morris A, et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg 1997; 174: 258-65.
151. Petty JK, He K, Corless CL, Vetto JT, Weinberg AD. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 2002; 183: 512-8.
152. Ladanyi A, Somlai B, Gilde K, et al. T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 10: 521-30.
153. Durkop H, Latza U, Himmelreich P, Stein H. Expression of the human OX40 (hOX40) antigen in normal and neoplastic tissues. Br J Haematol 1995; 91: 927-31.
154. Weinberg AD, Evans DE, Thalhofer C, Shi T, Prell RA. The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J Leukoc Biol 2004; 75: 962-72.
155. Andarini S, Kikuchi T, Nukiwa M, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res 2004; 64: 3281-7.
156. Kaneko H, Hori T, Yanagita S, Kadowaki N, Uchiyama T. Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo. Exp Hematol 2005; 33: 336-43.
157. Morris A, Vetto JT, Ramstad T, et al. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res Treat 2001; 67: 71-80.
158. Ali SA, Ahmad M, Lynam J, et al. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 2004; 22: 3585-94.
159. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000; 164: 2160-9.
160. Kjaergaard J, Tanaka J, Kim JA, et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor iummunogenicity and anatomic site of tumor growth Cancer Res 2000; 60: 5514-21.
161. Pan PY, Zang Y, Weber K, Meseck ML, Chen SH. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther 2002; 6: 528-36.
162. Gri G, Gallo E, Di Carlo E, Musiani P, Colombo MP. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J Immunol 2003; 170: 99-106.
163. Biagi E, Dotti G, Yvon E, et al. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood 2005; 105: 2436-42.
164. Kjaergaard J, Peng L, Cohen PA, et al. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 2001; 167: 6669-77.
165. Song A, Tang X, Harms KM, Croft M. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen, in J. Immunol. (inpress). 2005.
166. Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med 2001; 7: 907-12.
167. Ma BY, Mikolajczak SA, Danesh A, et al. The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells. Blood 2005;
168. de Jong EC, Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol 2002; 168: 1704-9.
169. Kim MY, Anderson G, White A, et al. OX40 Ligand and CD30 Ligand Are Expressed on Adult but Not Neonatal CD4+CD3-Inducer Cells: Evidence That IL-7 Signals Regulate CD30 Ligand but Not OX40 Ligand Expression. J Immunol 2005; 174: 6686-91.
170. Baumann R, Yousefi S, Simon D, et al. Functional expression of CD134 by neutrophils. Eur J Immunol 2004; 34: 2268-75.
171. Imura A, Hori T, Imada K, et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J Exp Med 1996; 183: 2185-95.
172. Murata K, Nose M, Ndhlovu LC, et al. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 2002; 169: 4628-36.
173. Dawicki W, Bertram EM, Sharpe AH, Watts TH. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 2004; 173: 5944-51.
174. Hoshino A, Tanaka Y, Akiba H, et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol 2003; 33: 861-9.
175. Mottonen M, Heikkinen J, Mustonen L, et al. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140: 360-7.
176. Matsumura Y, Imura A, Hori T, Uchiyama T, Imamura S. Localization of OX40/gp34 in inflammatory skin diseases: a clue to elucidate the interaction between activated T cells and endothelial cells in infiltration. Arch Dermatol Res 1997; 289: 653-6.
177. Aten J, Roos A, Claessen N, et al. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 2000; 11: 1426-38.
178. Tateyama M, Fujihara K, Ishii N, et al. Expression of OX40 in muscles of polymyositis and granulomatous myopathy. J Neurol Sci 2002; 194: 29-34.
179. Seko Y, Takahashi N, Oshima H, et al. Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by coxsackie virus B3. J Pathol 1999; 188: 423-30.
180. Seko Y, Takahashi N, Oshima H, et al. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3. J Pathol 2001; 195: 593-603.
181. Seko Y, Ishiyama S, Nishikawa T, et al. Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy. Cardiovasc Pathol 2002; 11: 166-70.
182. Streeter PR, Zhang X, Tittle TV, et al. CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease. Biol Blood Marrow Transplant 2004; 10: 298-309.
183. Sousa AE, Chaves AF, Doroana M, Antunes F, Victorino RM. Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery. Clin Exp Immunol 1999; 116: 307-15.
184. Buenafe AC, Weinberg AD, Culbertson NE, Vandenbark AA, Offher H. V beta CDR3 motifs associated with BP recognition are enriched in OX-40+ spinal cord T cells of Lewis rats with EAE. J Neurosci Res 1996; 44: 562-7.
185. Roos A, Claessen N, Weening JJ, Aten J. Enhanced T lymphocyte expression of LFA-1, ICAM-1, and the TNF receptor family member OX40 in HgC12-induced systemic autoimmunity. Scand J Immunol 1996; 43: 507-18.
186. Roos A, Claessen N, Schilder-Tol EJ, Weening JJ, Aten J. Differential expression of T-cell adhesion molecules and LFA-1-dependent intercellular adhesion in HgC12-induced autoimmunity and immune suppression. Scand J Immunol. 1998; 48: 389-96.
187. Takeda I, Ine S, Killeen N, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004; 172: 3580-9.
188. Yuan X, Salama AD, Dong V, et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 2003; 170: 2949-55.
189. Zubairi S, Sanos SL, Hill S, Kaye PM. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol 2004; 34: 1433-40.
190. Florido M, Borges M, Yagita H, Appelberg R. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD 137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium. J Leukoc Biol 2004; 76: 1039-46.
191. Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM. The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. Blood 1999; 93: 3487-93.
192. Jones D, Dorfman DM. Phenotypic characterization of subsets of T cell lymphoma: towards a functional classification of T cell lymphoma. Leuk Lymphoma 2001; 40: 449-59.
193. Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 2004; 103: 236-41.
194. Kurihara K, Harashima N, Hanabuchi S, et al. Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer 2005; 114: 257-67.
195. Yamaguchi T, Ohshima K, Tsuchiya T, et al. The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2-associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lymphoma. Eur J Dermatol 2003; 13: 553-9.
196. Ramstad T, Lawnicki L, Vetto J, Weinberg A. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am J Surg 2000; 179: 400-6.
197. Gniadecki R, Rossen K. Expression of T-cell activation marker CD134 (OX40) in lymphomatoid papulosis. Br J Dermatol 2003; 148: 885-91.
198. Dannull J, Nair S, Su Z, et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2005; 105: 3206-13.
199. Curti A, Parenza M, Colombo MP. Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 2003; 101: 568-75.
200. Lustgarten J, Dominguez AL, Thoman M. Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 2004; 173: 4510-5.
201. Yanagita S, Hori T, Matsubara Y, Ishikawa T, Uchiyama T. Retroviral transduction of acute myeloid leukaemia-derived dendritic cells with OX40 ligand augments their antigen presenting activity. Br J Haematol 2004; 124: 454-62.
202. Lee SJ, Myers L, Muralimohan G, et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol 2004; 173: 3002-12.